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Summary 
Natural killer (NK) cells play a crucial role in innate immunity against tumors 
and infections. Infected cells and tumor cells frequently upregulate ligands for 
the activating NK cell receptor NKG2D. Here we show that deregulated H-Ras 
activation induces the expression of Raet1 Family NK Receptor Ligands. H-
Ras 12V-induced NKG2D ligand upregulation depended on Raf, MEK and 
PI3K, but not the DNA damage response-initiating kinases ATM/ATR. 
Upregulation of NKG2D ligands by H-Ras 12V increased sensitivity of cells to 
NK cell-mediated cytotoxicity. In summary, our data suggest that hyperactive 
Ras activity is linked to innate immune responses, which can contribute to 
immune surveillance of cancer. 
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1.1 Natural killer cells  
Before 1970s, lymphocytes were classified as either T cells or B cells 
(Greenberg, 1994). It was only until 1973, Greenberg and Roitt discovered 
“null” killer cells that were neither of the two cell types, indicating the existence 
of a new class of killer lymphocytes (Greenberg et al., 1973).  A year later, 
these cells were found to have “spontaneous” cytotoxicity towards target cells 
without prior immunization or antibody (Greenberg and Playfair, 1974). In 
1975, Kiessling and colleagues described similar findings and finally termed 
the subset of cells “natural” killer (NK) cells (Kiessling et al., 1975a; Kiessling 
et al., 1975b).  
NK cells are part of innate immunity; they do not undergo gene 
rearrangement, which is used by B and T cells to create large repertoires of 
antigen specific receptors (Raulet and Held, 1995).  Consistent with their role 
in innate immunity, NK cells are widely distributed in the body. For instance 
they are found in lymph nodes, bone marrow, spleen, peripheral blood, liver 
and lung, etc (Gregoire et al., 2007). Nevertheless, they represent a small 
fraction of total lymphocytes - from 2% in mouse spleen to 10% in mouse lung 
and from 2% to 18% in human peripheral blood (Gregoire et al., 2007). 
NK cells play a crucial role in innate immune surveillance by targeting 
tumor cells and virus-infected cells. They kill sensitive target cells by polarized 
release of perforin-containing secretory lysosomes and production of 
proinflammatory cytokines like TNF-! and IFN-" in response to soluble 
mediators such as IL-12 and IL-18 (Bryceson and Long, 2008). The NK cells 
discriminate target cells from other healthy “self” cells by a variety of cell 
surface activating and inhibitory receptors. The integration and balance of 
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activating and inhibitory signals upon interaction with neighboring cells govern 
the dynamic equilibrium NK cell activation (Raulet and Vance, 2006).  
Normal adult body cells are usually protected from NK cell killing as 
activating signals delivered by stimulatory ligands are balanced by inhibitory 
signals delivered by self-MHC class I molecules. Nevertheless, transformation 
and infection often results in downregulation or lost expression of self-MHC 
class I molecules. As a result, NK cell inhibitory receptors do not receive 
enough negative signals. Therefore, the activating signals from target cells 
are unopposed, leading to NK-cell activation and target-cell lysis. This is 
known as “missing- self” recognition (Raulet and Vance, 2006). In addition, 
cellular transformation or viral infection frequently induces expression of 
activating ligands, so that constitutive inhibition delivered by inhibitory 
receptors is overcome. This is known as “induced-self” recognition (Raulet 
and Vance, 2006). “Missing-self” and “induced-self” recognition are not 
mutually exclusive, they may cooperate to provide NK cells to generate 




Figure 1. The balance of inhibitory and stimulatory signals received by a 
natural killer cell determines the outcome of interactions with target 
cells. [Adapted from (Raulet and Vance, 2006)] 
 
 
There are various NK cell inhibitory receptors, which bind to different 
classes of MHC class I molecules (Table 1). They include, for instance, Ly49-
family members in mice, KIR-family members in humans and NKG2A found in 
both mice and humans. Besides, there are also inhibitory receptors that are 
specific for non-MHC class I molecules (Raulet and Vance, 2006). Similarly, 
there is a wide range of activating receptors, like natural cytotoxic receptors 
(NCRs) (such as NKp30, NKp44, NKp46 and NKp80), DNAM-1, and the 
lectin-like NKG2D receptor that recognizes ligands that are induced in 
stressed situations and is crucial to NK cell-mediated immunosurveillance 






























Transporter associated with 
antigen processing 1 
(TAP1). A molecule that 
transports short peptides from 
the cytosol to the endoplasmic 
reticulum and is required for 
normal cell-surface expression 
of MHC class I molecules. 
fail to express a full complement of normal self MHC 
class I proteins. This was first shown in studies of bone-
marrow transplantation in which donor bone-marrow 
cells lacking an MHC class I allele of the recipient 
were often rejected by NK cells19. Perhaps the clearest 
demonstration of missing-self rejection is the potent 
elimination of bone-marrow cells or lymphoblasts 
that do not express MHC class I molecules (such as 
those from mice that are deficient in β2-microglobulin 
(β2m), transporter associated with antigen processing 1 
(TAP1) or both H2-Kb and H2-Db) by NK cells from 
an otherwise genetically identical MHC-class-I-
expressing host20–25. It is important to emphasize that 
missing-self recognition does not operate independ-
ently of stimulatory recognition. To lyse target cells 
or to produce effector cytokines, NK cells, similar to 
T cells, must be triggered by stimulatory receptors. In 
the case of missing-self recognition of bone-marrow 
cells or lymphocytes, the target cells are not diseased, 
indicating that even normal cells express ligands that 
engage stimulatory receptors at the surface of NK 
cells. A variety of stimulatory ligands are present at the 
surface of normal cells from mice of different genetic 
backgrounds. For example, the MHC molecule H2-Dd 
can be a stimulatory ligand in H2d mice26, and a ligand 
for the stimulatory receptor NKG2D (NK group 2, 
member D) is stimulatory in mice of the BALB/c 
background27. Bone-marrow cells from C57BL/6 mice 
seem to express yet another, unidentified, stimulatory 
ligand, because grafts from β2m-deficient C57BL/6 
mice are rejected by NKG2D-deficient C57BL/6 hosts 
(N. Guerra and D.H.R., unpublished observations). 
So missing-self recognition of normal (non-diseased) 
cells by NK cells depends on both stimulation and the 
absence of inhibition.
The need for self-tolerance. That normal cells express 
stimulatory ligands for NK cells highlights the poten-
tial autoreactivity of NK cells. If such stimulation 
were unopposed, NK cells would presumably show 
auto immune activity and/or reject self bone-marrow 
cells or lymphoid cells. That this does not usually 
occur is partly because normal animals express MHC 
class I molecules and other molecules that can engage 
inhibitory receptors and counter the stimulatory sig-
nals. However, MHC class I molecules show enormous 
allelic variation, and individual inhibitory NK-cell 
receptors bind certain MHC class I variants but not 
others. MHC class I genes are inherited independently 
of NK-cell receptor genes28, so genetic mechanisms 
cannot ensure that the NK-cell receptors of an indi-
vidual show specificity for the appropriate self MHC 
class I molecules. Furthermore, a given MHC-class-I-
specific receptor is usually only expressed by a subset 
of NK cells, and the set of receptors that each NK cell 
expresses seems to be determined by a pro cess that 
is largely random11. Therefore, although many NK 
cells are self-tolerant as a result of the expression of 
inhibitory receptors for self MHC class I molecules, 
some NK cells might arise that do not express such 
receptors. So a key issue to be addressed is whether 
such NK cells arise and, if they do, how these cells are 
prevented from attacking their host.
Possible mechanisms of self-tolerance
Several mechanisms that lead to self-tolerance of 
NK cells have been proposed (FIG. 2).
The ‘at-least-one’ model. An early model to explain 
NK-cell self-tolerance proposed that a developmen-
tal process is superimposed on the initially random 
expression of MHC-class-I-specific receptors such 
that every mature NK cell is somehow endowed with 
at least one inhibitory receptor specific for a self MHC 
class I molecule15,17,29 (FIG. 2b). Two processes have been 
considered. First, a cellular selection process could 
ensure the selective expansion or survival of only those 
immature NK cells that happened to express inhibitory 
receptors specific for self MHC class I molecules, or a 
selection process could involve the specific deletion of 
NK cells that lack inhibitory receptors for self MHC 
class I molecules. Second, it is possible that individual 
developing NK cells could sequentially express or 
‘audition’ each receptor encoded in its genome until 
a self-MHC-class-I-specific receptor is eventually 
expressed29–31.
Figure1 | The balance of inhibitory and stimulatory signals received by a natural 
killer cell determines the outcome of interactions with target cells. Normal target 
cells are protected from killing by natural killer (NK) cells when signals delivered by 
stimulatory ligands are balanced by inhibitory signals delivered by self MHC class I 
molecules. If, however, a target cell loses expression of self MHC class I molecules (as a 
result of transformation or infection), then the stimulatory signals delivered by the target 
cell are unopposed, resulting in NK-cell activation and target-cell lysis (known as missing-
self recognition). Transformation or infection might also induce expression of stimulatory 
ligands such that constitutive inhibition delivered by inhibitory receptors is overcome 
(known as induced-self recognition). In many contexts, it is probable that both missing-
self and induced-self recognition operate simultaneously to provide NK cells with the 
maximal ability to discriminate between normal cells and transformed or infected 
target cells.
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Table 1. Receptors on natural killer cells. [Adapted from (Raulet and 
Vance, 2006)] 
 
molecules, as occurs frequently in virus-infected cells 
or tumour cells (FIG . 1). The recognition and lysis of 
MHC-class-Ilow target cells by NK cells is aptly referred 
to as missing-self recognition18. It is thought that the 
downregulation of MHC class I molecules by virus-
infected cells is a strategy to evade cytolysis by CD8+ 
T cells and that missing-self recognition by NK cells is 
a counter-response by the immune system.
Importantly, viral infection or transformation 
of target cells does not seem to be a prerequisite for 
missing-self recognition. Even untransformed, un infected 
target cells can be lysed by NK cells if the target cells 









NKG2A is inhibitory; NKG2C and NKG2E are stimulatory; Qa-1 and HLA-E bind 




Various MHC class I molecules Several Ly49 genes are present in mice; not functional in humans 73








Various MHC class I molecules Several KIR genes are present in humans, but not present in mice 76
LIR1 
(ILT2, LILRB1)
Various HLA class I molecules
HCMV-encoded UL18
LIR1 is present in humans, but not present in  mice; LIR1 is expressed by several 
cell lineages
77,78
Stimulatory receptors (specific for non-MHC class I molecules)




MICA and MICB (humans)
NKG2D has low homology to NKG2A, NKG2C and NKG2E; NKG2D binds diverse 
ligands in mice and humans; ligands are induced by stress and/or DNA damage
79–84
Ly49H MCMV-encoded m157 – 85–89
Ly49D H2-Dd – 90–92
FcγRIII Antibody-coated target cells – 93
NKR-P1C ND NKR-P1C is a pan NK-cell marker in C57BL/6 mice 49
NKR-P1F CLR-G – 49
NKp30 ND HCMV-encoded pp65 might be an antagonist; Nkp30 is a pseudogene in most 
mouse strains
94,95
NKp44 ND; possibly viral 
haemagglutinin 
– 96,97
NKp46 ND; possibly viral 
haemagglutinin 
NKp46 is present in humans and mice 97,98
2B4 
(CD244)








Inhibitory receptors (specific for non-MHC class I molecules)
2B4 
(CD244)
CD48 2B4 functions to inhibit or stimulate, depending on the associated signalling 
molecules
99
KLRG1 (MAFA) Cadherins – 51,101–103
NKR-P1B CLR-B – 49,50
CEACAM1 CEACAM1 – 34
This is not a comprehensive list; selected receptors particularly relevant to this Review were chosen. Common alternative abbreviations are shown in parentheses. 
Only key references are indicated. For more details, see several recent reviews10, 11. CEACAM1, carcinoembryonic-antigen-related cell-adhesion molecule 1; 
CLR, C-type-lectin-related; DNAM, DNAX accessory molecule; FcγRIII, low-affinity Fc receptor for IgG; H60, histocompatibility 60; HCMV, human cytomegalovirus; 
ILT2,  immunoglobulin-like transcript 2; KIR, killer-cell immunoglobulin-like receptor; KLRG1, killer-cell lectin-like receptor G1; LILRB1, leukocyte immunoglobulin-
like receptor, subfamily B, member 1; LIR1, leukocyte immunoglobulin-like receptor 1; MAFA, mast-cell function-associated antigen; MCMV, mouse cytomegalovirus; 
MIC , MHC-class-I-polypeptide-related sequence; MULT1, murine ULBP-like transcript 1; ND, not determined; NK, natural killer; NKG2, NK group 2; NKp, NK-cell 
protein; NKR-P, NK-cell receptor protein; RAE1, retinoic acid early transcript 1; ULBP, cytomegalovirus UL16-binding protein.
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1.2 NKG2D and NKG2D ligands 
NKG2D was initially identified in a screen for genes preferentially 
expressed by human NK cells (Houchins et al., 1991; Houchins et al., 1990), 
but it is distinct from other NKG2 genes: NKG2A, NKG2C and NKG2E are 
present as inhibitory heterodimers with another protein (CD94) and recognize 
a non-classical MHC class I molecule known as HLA-E (in humans) or Qa1 (in 
mice) (Raulet, 2003a). NKG2D is a homodimeric activating receptor which 
recognizes one of several cell surface molecules that are only distantly related 
to MHC class I molecules (Raulet, 2003a). NKG2D is expressed on virtually 
all NK cells and is usually referred to as an NK receptor (Gasser and Raulet, 
2006), although it is also expressed on various lymphoid and myeloid cell 
types. For instance, NKG2D is expressed on some CD8+ αβT cells and 
γδelcells in mouse and human, as well as on activated macrophages in 
mouse (Gasser and Raulet, 2006b; Raulet, 2003b). 
Among the activating NK cell receptors, NKG2D was shown to have 
key roles in tumor rejection. For instance, tumor-cell lines transfected with 
NKG2D ligands have enhanced sensitivity to lysis by NK cells (Jamieson et 
al., 2002). On the other hand, the lysis of tumor cells that naturally express 
NKG2D ligands is partially inhibited by NKG2D-specific antibodies 
(Diefenbach et al., 2000a; Diefenbach et al., 2000b; Pende et al., 2002). 
Similarly, NK cells lacking the expression of NKG2D fail to reject tumors 
(Guerra et al., 2008) (Fig. 2). Besides, the ability of CD8+ T cells or !"T cells 
to target tumor cells is also increased if the tumor cells express NKG2D 






Figure 2. NK cells lacking the expression of NKG2D fail to recognize 
transformed epithelial cells bearing NKG2D ligand Rae-1 Proteins. 
[Adapted from (Ljunggren, 2008) and (Guerra et al., 2008)] 
 
 
NKG2D is a type II transmembrane protein with a charged amino acid 
residue which helps to recruit adaptor molecules like DNAX-activating protein 
of 10 kDa (DAP 10) or DAP12 through immunoreceptor tyrosine-based 
activation motifs (ITAMs) (Raulet, 2003b). Receptor engagement induces 
tyrosine phosphorylation of the ITAMs, recruitment and activation of SYK or 
ζ-chain-associated protein 70 kDa (ZAP70) tyrosine kinases, and 
phosphorylation of downstream effectors that trigger cell activation (Raulet, 
2003a) (Fig. 3). 
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Figure 3. NKG2D recruits DAP10 and DAP12 through ITAMs. [Adapted 
from (Raulet, 2003a)] 
 
The ligands for NKG2D are usually expressed at low levels or absent in 
normal adult cells (Takada et al., 2008; Zou et al., 1996), but upregulated in 
“stressed” conditions (Raulet, 2003b). There are diverse NKG2D ligands with 
distinct expression patterns and different ligand-receptor binding affinity 
identified both in mice and human (Fig. 4). In mice, the NKG2D ligands 
include retinoic acid early transcript 1 (Rae-1), histocompatibility 60 (H60) and 
mouse UL16-binding protein-like transcript 1 (Mult1) (Raulet, 2003b). In 
humans, there are Rae-1 orthologues UL16-binding proteins (ULBPs, AKA 
RAET1 family), MHC class-I-related protein A (MICA) and MICB (Raulet, 
2003a).  
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lymphocyte subsets. A monoclonal antibody was pre-
pared that blocked the interaction, and the antibody was
subsequently shown to bind NKG2D9. Further analysis
showed that MICB — a close relative of MICA — also
binds NKG2D. No functional homologues of MICA or
MICB have been identified in the mouse MHC,
although two mouse genes with some similarities were
recently identified on mouse chromosome 7, which is
close to the leukocyte-receptor gene complex14.
Mouse Rae1, H60 and Mult1. Two research groups used
soluble forms of mouse NKG2D as staining reagents to
detect ligands expressed by mouse cells. Expression of
putative ligands expressed by various mouse tumour-cell
lines was observed, and cDNAs encoding the ligands were
subsequently cloned7,15. Surprisingly, two distinct but
related proteins, neither similar to MICA nor MICB, were
identified as ligands. One of the proteins was retinoic acid
early transcript 1 (Rae1), a lipid-linked membrane pro-
tein, which had previously been cloned based on its rapid
induction of expression by F9 embryocarcinoma cells
after treatment with retinoic acid16. Rae1β is a member of
a subfamily of several closely related (>98% amino-acid
identity) proteins, which also show allelic diversity17,18.
The genes and/or alleles identified so far are known as
Rae1α–Rae1ε. The other ligand identified was histocom-
patibility 60 (H60), a type-1 transmembrane protein,
which had previously been cloned based on its role as a
minor histocompatibility antigen19. Mouse UL16-binding
protein-like transcript 1 (Mult1) — a third relative of this
growing protein family — was identified more recently
and shown to bind NKG2D20,21. In pairwise combina-
tions, Rae1, H60 and Mult1 are only 20–28% identical in
their amino-acid sequences21 (FIG. 2).
ULBP or human RAET1. A distinct approach identified
three related human proteins that bind to the UL16
protein of human cytomegalovirus (HCMV) and are
encoded by a gene family that is homologous to the
Rae1/H60/Mult1 gene family22. UL16 was studied
because it was a candidate virus protein that was involved
in evasion of the immune response. The proteins bound
by UL16 were designated UL16-binding proteins
(ULBPs). Other researchers named the same molecules
human RAET1 proteins, in recognition of their related-
ness to the mouse proteins, and identified new members,
increasing the gene family to at least six functional genes
and two pseudogenes23–25. Most of the RAET1 proteins,
similar to the mouse Rae1 proteins, are attached to the
plasma membrane with a lipid linkage and have been
shown to bind human NKG2D. However, two family
members, RAET1E (ULBP4) and RAET1G, have trans-
membrane domains23,26. Similar to their mouse counter-
parts, human RAET1 proteins have considerable
sequence diversity, ranging as low as 35% amino-acid
identity in pairwise comparisons23 (FIG. 2).
Ligand genes and domain structure. The mouse Rae1/
H60/Mult1 and human RAET1 proteins are relatively dis-
tinct in sequence (FIG. 2), but all have a similar and unique
domain structure, consisting of two ectodomains that are
most mouse intestinal intraepithelial γδT cells do not6.A
large fraction of NK1.1+ T cells also express NKG2D6.
Finally, NKG2D is expressed by mouse peritoneal exu-
date macrophages that are activated with lipopolysac-
charide (LPS), interferon-α (IFN-α) mixed with IFN-β,
or IFN-γ6,7.
Most human NK cells also express NKG2D, and
the levels are increased by exposure to interleukin-15
(IL-15)8. The pattern of receptor expression in humans
differs from that in mice in some other cell lineages
(TABLE 1). Although resting mouse CD8+ T cells do not
express NKG2D, almost all human peripheral blood
CD8+ T cells express the receptor before activation,
including those that lack expression of the co-stimulatory
molecule CD28 (REFS 9,10). Furthermore, essentially all
peripheral blood γδT cells express NKG2D9, in contrast
to the more selective expression by mouse γδT cells6. In
addition, although intestinal intraepithelial γδT cells lack
NKG2D expression in mice, almost all human intestinal
intraepithelial γδ T cells express NKG2D at low levels,
which can be increased by incubation with IL-15 (REF. 11).
Also unlike the situation in mice, expression of NKG2D
was not detected on LPS-activated human macro-
phages12. Finally, although human CD4+ T cells, similar to
mouse CD4+ T cells, do not normally express NKG2D9,
upregulation of expression was observed in a fraction of
CD4+ T cells from patients with rheumatoid arthritis13.
Surprising diversity of NKG2D ligands
MICA and MICB. The first evidence for a protein that
binds to NKG2D came from a study showing that a
soluble form of MHC class-I-chain-related protein A
(MICA) — a non-classical class I molecule that is
encoded in the human MHC — binds to various
The 'NK complex'

















Figure 1 | The NKG2D gene and the NKG2D receptor. a | NKG2D is encoded in the
natural killer (NK) gene complex (NKC). The neighbouring NKG2 genes, despite their 
names, are dissimilar in sequence, specificity and function. b | The NKG2D receptor is a type-2
transmembrane homodimer that contains charged residues in the transmembrane segments,
associates with DNAX-activating protein of 10 kDa (DAP10) and DAP12 signalling molecules,




Figure 4. The diverse nature of NKG2D ligands. A dendrogram 
representing the relatedness of different NKG2D ligands to each other and to 
various MHC class I molecules. The extent of the sequence relatedness 
between two proteins is shown by the total distance of the lines that connect 
those proteins. [Adapted from (Raulet, 2003a)] 
 
 
Murine NKG2D ligand Rae-1 are glycosylphosphatidylinositol (GPI)-
anchored proteins on the plasma membrane (Nomura et al., 1996a). There 
are five Rae-1 isoforms described to-date (!, #, ", $ and %), with more than 
90% sequence identities (Raulet, 2003a). They are expressed at the cell 
surface in a strain-specific manner as either Rae-1!, #, or ! in BALB/c mice, 
or Rae-1" and $ in C57BL/6 mice (Cerwenka et al., 2000; Diefenbach et al., 
2000a). Similarly, there are three known H60 family ligands, named H60a, b 
and c (Takada et al., 2008). H60a transcript is detected in various tissues in 
BALB/c mice, but it is not expressed in adult healthy C57BL/6 mice 
(Carayannopoulos et al., 2002). Whereas H60b transcript can be detected at 
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induction of MICA, MICB or ULBP expression by cells
infected with HCMV has been observed in cultures of
primary fibroblasts and endothelial cells, and in patient
samples10,43. MICA expression was also upregulated by
cells as a result of the binding of Escherichia coli adhesin
AfaE to cellular CD55 (REF. 44) and by cells infected with
Mycobacterium tuberculosis 45. Mouse fibroblasts infected
with mouse CMV (MCMV) upregulated the expression
of Rae1, but not H60, transcripts46. Evidence for the role
of NKG2D and its ligands in protection from infection
with CMV is discussed later.
The upregulation of expression of NKG2D ligands
by tumour cells or infected cells indicates that the sys-
tem is ‘wired’ to respond to signalling events or com-
binations of signalling events that occur in distressed
cells, but not normal cells. In this system, apparently
the ce l l itse l f must recogn ize that it is undergoing
pathological changes and respond by expressing mole-
cu les that a ler t the immune system . In th is respect ,
together w ith the fact that NKG2D  l igands are se l f
molecules, the logic of the system seems to differ fun-
damentally from that proposed for Toll-like receptors
(TLRs), which generally recognize foreign molecular
patterns47 (FIG. 4).
Stimulation of immune cells through NKG2D
NKG2D functions as a stimulatory receptor in various
cell types. So far, there is no evidence that the different
ligands induce qualitatively distinct biological effects in
responding cells, though this remains a clear possibil-
ity. M inimally, the various ligands would be predicted
to differ quant itat ively in their effects based on the
marked differences in their affinity for NKG2D (FIG. 3).
At present, the relevance of such differences has not
been documented. The consequences of NKG2D stim-
u lat ion in var ious NKG2D-expressing cel l types are
described below.
Natural killer cells. Tumour-cell lines transfected with
NKG2D ligands have enhanced sensitivity to lysis by NK
cells7,9,15,22. In general, the lysis of tumour cells that natu-
rally express NKG2D  ligands is partially inhibited by
NKG2D-specific antibodies, indicating that NKG2D is
an important receptor in the recognition of target cells
by NK cells, but not the only one6,41. Indeed, some target
cells that lack expression of NKG2D ligands are neverthe-
less sensitive to NK cells6, in line with the identification of
other NK-cell stimulatory receptors that participate in
tumour-cell recognition48.
Antibody crosslinking of NKG2D expressed by IL-2-
or polyI:C-activated mouse NK cells triggers calcium
mobilization and IFN-γ production6. In human NK cells,
crosslinking with multivalent soluble ligands (ULBPs)
stimulates the production of several cytokines including
IFN-γ, tumour-necrosis factor (TNF), lymphotoxin and
granulocyte–macrophage colony-stimulating factor
(GM-CSF), as well as chemokines such as CCL4
(macrophage inflammatory protein 1β, MIP1β) and
CCL1 (I-309)8,22,49. Limiting concentrations of IL-12 act
synergistically with ULBPs to trigger the production of
cytokines by human NK cells8,22,49. Unlike multivalent
Mult1 mRNA, but stain poorly with NKG2D tetramers21.
However, ULBPs and probably Mult1 are expressed at
functional levels on the cell surface of numerous
tumour-cell lines, indicating that these molecules might
be regulated at a level other than transcription21,41. At
present, H60 is the only ligand that is known to be
expr ssed at high levels by normal adult cells, in particu-
lar thymocytes in BALB/c (not C57BL/6) mice42. It is
probable, however, that the thymus is inaccessible to
most mature lymphocytes that are potentially responsive
to H60,which might help to explain the failure of these
mice  develop H60-induced NK-cell-med ated
autoimmunity or tolerance.
Unlike MICA or MICB, heat-shock elements have not
been implicated in regulating the expression of Rae1,
H60, Mult1 or ULBPs. The expression of Rae1 is upregu-
lated in the F9 embryocarcinoma cell line by retinoic
acid16, but regulation of Rae1 genes by retinoic acid in
other cells has not been documented. In general, cell pro-
liferation by itself is insufficient for induction of the lig-
ands, as indicated by the fact that late-stage mouse
embryos have low levels of Rae1 expression18 and normal
proliferating cells in culture usually do not upregulate the
expression of ligands to marked levels7. So, the signalling
events that are responsible for the upregulation of Rae1 or
H60 expression by tumour cells are not known.
The expression of NKG2D  ligands is also upregu-

































Figure 2 | The diverse nature of NKG2D ligands. A dendrogram representing the relatedness
of different NKG2D ligands to each other and to various MHC class I molecules. The extent of 
the sequence relatedness between two proteins is shown by the total distance of the lines that
connect those protein . As a guide, retinoic acid early transcript 1 (Rae1) and H60 proteins are
20–28% identical at the amino-acid level. The NKG2D ligands are shown in blue (mouse) or red
(human). The box groups the larger family consisting of human and mouse Rae1, H60, Mult1,
ULBP and RAET1 proteins, to distinguish them from the MHC class-I-chain-related protein A
(MICA) and MICB ligands. Figure reproduced with permission from REF. 21 © Wiley-VCH (2003).
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low levels in various tissues in both BALB/c and B6 mice, H60c transcription 
is largely restricted to the skin (Takada et al., 2008). H60c is a GPI-anchored 
protein like Rae-1 isoforms. In contrast, H60a, H60b and Mult1 have 
transmembrane regions (Takada et al., 2008).  
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1.3. Mechanism for NKG2D ligand induction 
Despite the remarkable ability of NKG2D ligands in triggering immune 
responses, the mechanism for their upregulation is poorly understood, and 
often vaguely described as “stress” or “distress”. Recently, we demonstrated 
that DNA damage response (DDR) could induce the NKG2D ligand 
expression via ataxia telangiectasia, mutated (ATM) or ATM- and Rad3-
related (ATR) protein kinases, and their downstream transducer kinases Chk1 
and Chk2 (Gasser et al., 2005) (Fig. 5). Conditional genetic deletion of ATR 
led to the blocking of DDR-induced NKG2D ligand expression (Gasser et al., 
2005). However, ex vivo fibroblasts spontaneously upregulate NKG2D ligands 
in presence of DNA damage response (DDR) inhibitors or in 3% oxygen (data 
not shown), which only minimally activates the DDR (Di Micco et al., 2008), 
suggesting that DDR-independent mechanisms must exist for the regulation 
of NKG2D ligands. Therefore, we began our search for such mechanisms.  
 
 
Figure 5. Genotoxic stress induces expression of NKG2D ligands and 
renders diseased cells sensitive to lysis by NK cells and other 
lymphocytes. [Adapted from (Gasser and Raulet, 2006a)] 
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 In addition to DNA damage, heat shock protein (Hsp) 70 was reported 
to induce NKG2D ligand expression in various cell lines followed by increased 
susceptibility to NK cell-mediated cytolysis (Kim et al., 2006). Extracellular 
Hsp 70 was also reported to induce the expression of NKG2D ligand, MICA, 
on dendritic cells (Qian et al. 2008). Consistent with the above, heat shock 
element was found in the promoter/regulatory regions of the MICA and MICB 
genes (Venkataraman et al., 2007). Nevertheless, heat shock did not regulate 
spontaneous NKG2D ligand expression (Gasser et al., 2005). Besides, we 
observed no increase of Hsp70 mRNA in murine fibroblasts that 
spontaneously upregulate NKG2D ligands (data not shown).  
We tested a number of stress conditions in C1 and C2 cell lines that 
have been derived from ovarian epithelial cell lines from p53-/- mice and 
transduced with K-ras and c-myc or Akt and c-myc respectively. NKG2D 
ligand upregulation was not observed in these cell lines by cell stress 
conditions including hyperoxia, hypoxia, exposure to inflammatory cytokines 
such as tumor necrosis factor (TNF), interferon or interleukin (IL)-6, or 
incubation in medium of pH6 or pH8.5 (Gasser et al., 2005). 
Recently, Mult1 was shown to be regulated post-translationally. 
Specifically, Mult1 protein was ubiquitinylated on lysines in the cytoplasmic 
tail, which induced subsequent lysosomal degradation (Nice et al., 2009). 
Moreover, Mult1 degradation and ubiquitination is reduced in response to 
stress imparted by heat shock or ultraviolet irradiation (Nice et al., 2009). In 
summary, our data suggest that pathways other than DNA damage and heat 
shock regulate NKG2D ligand expression. The goal of my project was to 
characterize these factors.  
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1.4 Ras oncogene and NKG2D ligands 
As oncogenes were reported to induce replicative stress and DNA 
damage (Di Micco et al., 2006), we wondered if replicative stress would 
induce NKG2D ligand expression. In support to such a hypothesis, earlier 
research has shown that by inducing a single oncogene of mutant H-Ras, a 
murine fibroblast cell line C3H 10T1/2 was more susceptible to NK cell-
mediated lysis (Trimble et al., 1986). For that reason, we overexpressed a 
number of oncogenes, previously shown to induce replicative stress in a cell 
line that expresses low levels of NKG2D ligands. Particularly, we tested if 
oncogenic H-Ras induced NKG2D ligand upregulation. 
The transforming ability of rat-derived Harvey and Kirstern murine 
sarcoma retrovirus lead to the discovery of homologues of Ras proto-
oncogenes in rat, mouse and human genomes (Karnoub and Weinberg, 
2008). Mutations in Ras proto-oncogenes that are required for normal cellular 
functions, renders them active oncogenes, an event associated with 
tumorigenesis. Ras proteins are small GTPases that possess an intrinsic GTP 
hydrolysis activity that shuttles them from an active to an inactive signaling 
state (Gilman, 1987). Oncogenic mutations, for instance at codon 12, 13 and 
61 of Ras isoforms (H-, K- and N-Ras) impair their hydrolytic function, and 
locks them perpetually in their “on” states (Clark et al., 1985; Der et al., 1986; 
Gibbs et al., 1984; McGrath et al., 1984). 
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The induction of programmed 
cell death by the detachment 
of cells from the extracellular 
matrix.
Downstream effector signalling
The mechanistic details of how Ras proteins function in 
cellular signalling were lacking for much of the 1980s. 
At the time, however, several Ras-induced changes in 
cellular biochemistry had been catalogued by a number 
of research groups. Among the earliest of such reports 
came from the Feramisco laboratory in 1986, which 
described the activation of phospholipase A2, a calcium-
dependent glycerophospholipid esterase, within minutes 
of the microinjection of Ras proteins into quiescent 
rat-embryo fibroblasts105. Other groups reported a 
number of similar biochemical changes that are associ-
ated with Ras expression, such as the phosphorylation 
of mitochondrial proteins106, the phosphorylation of 
plasma-membrane components107, increased diacyl-
glycerol levels108–110, enhanced phospholipid metabolism 
and the activation of protein kinase C (PKC)111–113. At 
the time, it was not clear whether such biochemical 
alterations were secondary, pleiotropic effects of the 
forced overexpression of Ras. In 1988, Fukami and col-
leagues showed that antibodies that were injected against 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) 
inhibited Ras-induced mitogenesis114, indicating that 
some of the downstream biochemical responses to Ras 
activation are actually crucial to its cell-biological effects. 
Experiments such as these fuelled the search for the direct 
downstream signalling effectors that interact directly with 
Ras and mediate its various functions (FIG. 5).
The connection with RAF1 and the MAPK cascade. In 
1993, four groups reported the direct interaction of Ras 
with the RAF1 Ser/Thr kinase, which was the first bona 
fide mammalian Ras effector to be identified115–118. RAF1, 
originally discovered through its association with avian 
and murine transforming retroviruses, was extensively 
characterized over subsequent years. This research 
revealed the ability of RAF1 to signal through a path-
way that involves the mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase (ERK) 
kinase (MEK), ERK1/2, and the E26-transcription fac-
tor proteins (ETS). This signalling cascade became the 
prototype of a number of other plasma-membrane-to-
nucleus signal-transduction pathways. Interestingly, 
the role of MAPK signalling in Ras biology, initially 
described in 1992 by Leevers, Wood and colleagues119,120, 
has been characterized by several groups and shown to 
be both sufficient and necessary for Ras-induced trans-
formation of murine cell lines121–124. Furthermore, the 
subsequent identification of B-Raf mutations in cancers, 
in non-overlapping frequencies with Ras mutations (for 
example, in melanoma and colon cancer125) emphasized 
an important role for aberrant Raf–MEK–ERK signalling 
in oncogenesis.
Ras signals through PI3K and Ral proteins. A year later, 
two other Ras effectors were identified: the p110 cata-
lytic subunit of the class I phosphoinositide 3-kinases 
(PI3Ks)126 and the guanine nucleotide-exchange factors 
for the Ras-like (RalA and RalB) small GTPases (Ral 
guanine nucleotide-dissociation stimulator (RalGDS) 
and RalGDS-like protein (RGL))127–129. As with Raf, 
PI3K activity was shown to be required for Ras trans-
formation of NIH 3T3 cells130. Indeed, the anti-apoptotic 
effects of Ras were ascribed to the pro-survival activi-
ties of activated PI3K signalling through a pathway that 
involves the Ser/Thr kinase AKT/protein kinase B and 
the transcription factor nuclear factor-KB (NF-KB), both 
of which have crucial roles in preventing anoikis131–133.
Initial studies of the RalGDS–Ral pathway in rodent 
fibroblasts indicated a limited involvement of this effec-
tor pathway in Ras-mediated cell transformation134,135. 
Table 1 | Ras mutations in human cancers
Tissue H-Ras K-Ras N-Ras
Adrenal gland 1% 0% 5%
Biliary tract 0% 32% 1%
Bone 2% 1% 0%
Breast 1% 5% 1%
Central nervous system 0% 1% 2%
Cervix 9% 8% 1%
Endometrium 1% 14% 0%







Kidney 0% 1% 0%
Large intestine 0% 32% 3%
Liver 0% 7% 4%
Lung 1% 17% 1%
Meninges 0% 0% 0%
Oesophagus 1% 4% 0%
Ovary 0% 15% 4%
Pancreas 0% 60% 2%
Parathyroid 0% 0% 0%
Peritoneum 0% 6% ND
Pituitary 2% 0% 0%
Placenta 0% 0% 0%
Pleura 0% 0% 0%
Prostate 6% 8% 1%
Salivary gland 16% 4% 0%
Skin 5% 2% 19%
Small intestine 0% 20% 25%
Stomach 4% 6% 2%
Testis 0% 5% 4%
Thymus 0% 15% 0%




Urinary tract 12% 4% 3%
Data derived from the Catalogue of Somatic Mutations in 
Cancer (COSMIC) of the Wellcome Trust Sanger Institute, 
Cambridge, UK. ND, not determined.
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The three isoforms of H-, K- and N-Ras were shown to have similar 
functions but have different expression patterns in various tissues (Bachmann 
et al., 1997). Activation of individual Ras oncogenes was associated with 
different human cancers (Karnoub and Weinberg, 2008) (Table 2). Indeed, 
mouse genetic experiments suggested distinct functions of Ras isoforms in 
specific tissues throughout development. For instance, K-Ras-4B, but not K-
Ras-4A, was essential for embryogenesis, as K-Ras-4B-deficiency was 
embryonically lethal (Johnson et al., 1997; Koera et al., 1997). On the other 
hand, H-Ras and/or N-Ras-deficient mice developed normally and were viable 
(Esteban et al., 2001; Umanoff et al., 1995). Mice in which the H-Ras coding 
sequence was knocked into the locus of K-Ras were also shown to be viable 
(Potenza et al., 2005), indicating that H-Ras could compensate for K-Ras 
functions, whereas the expression profile controlled by promoters were more 
critical to their different roles.  
Alternative to specific tissue expressions, differential membrane 
localization is also important for Ras functions. For instance, plasma 
membrane-anchored K-Ras could induce transformation, whereas 
mitochondrial K-Ras induced apoptosis (Bivona et al., 2006). Moreover, 
although activated H-Ras was shown to be associated with both the Golgi 
apparatus and the endoplasmic reticulum (ER), only the ER-associated form 
could activate RAF/MEK/ERK signaling (Chiu et al., 2002) and transformation 
(Matallanas et al., 2006).  
Ras signaling has diverse effector functions (Fig. 6). Among them, the 
Raf/MEK/ERK, and PI3 kinase pathways were the best characterized. It is 
worth to point out that B-Raf mutations (for example, B-Raf V600E) in cancers 
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(like melanoma and colon cancer (Rajagopalan et al., 2002)) were non-
overlapping with Ras mutations, indicating an important role of aberrant 
Raf/MEK/ERK signaling in oncogenesis. As with Raf, PI3K activity was shown 
to be required for Ras transformation of NIH3T3 cells (Rodriguez-Viciana et 
al., 1997). Indeed, the anti-apoptotic effects of Ras were ascribed to the pro-
survival activities of the activated PI3K signaling through AKT and NK-&B 
(Marte and Downward, 1997). More recently, RalGEF has also been shown to 
participate in tumorigenesis and metastasis. RalB is specifically required for 
survival of tumor cells but not normal cells, whereas RalA is dispensable for 
survival, but is required for anchorage-independent proliferation (Chien et al., 
2006; Chien and White, 2003). 
 
 
Figure 6. Ras signaling networks. [Adapted from (Karnoub and Weinberg, 
2008)] 
 
Upstream of Ras, various growth factors leading to the activation of 
growth factor receptors signaling converge. For instance, it was observed that 
epidermal growth factor (EGF) resulted in increased GTPase activity of 
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cellular H-Ras in response to treatment with EGF (Kamata and Feramisco, 
1984). Therefore, unregulated growth factor signaling could also lead to 
uncontrolled proliferation and be a cause of tumorigenesis. For instance, 
overexpression of epidermal growth factor receptor (EGFR) and closely 
related ErbB2 has been associated with breast cancers ((reviewed in 
(Mendelsohn and Baselga, 2000). Furthermore, administration of blocking 
antibodies to the receptor like Herceptin (trastuzmab) was used for the 
treatment of ErbB2-overexpressing breast cancers (Baselga et al., 1998).  
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1.5 Objective and significance of the study 
Cancer is a leading cause of death worldwide and account for 7.6 
million deaths (around 13% of all deaths) in 2008 (Ferlay et al., 2010). Despite 
tremendous efforts worldwide in cancer research, the five-year overall survival 
rate of cancer patients barely increased by 30% over the last two decades  
(Howlader et al., 2011) (Table 3). 
 











Table 3. Five-year survival rates of cancer patients from 1975 to 2007. 
[Adapted from SEER Cancer Statistics Review, 1975-2008, National Cancer 
Institute. Bethesda, MD.] 
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Currently, standard cancer therapies include chemotherapy, radiation 
therapy and surgery. Besides the high costs associated with cancer 
treatments, cancer patients usually suffer from severe side effects due to 
systemic damage to healthy body cells caused by the chemo- and radio-
therapeutic agents, and often relapse with cancer. Therefore, there is an 
urgent need to develop alternative and effective treatments for cancer with 
overall low cytotoxicity. One such possibility lies in NK cell-mediated 
immunotherapy, where we deploy the body’s innate immune system to defend 
against cancer.  
The importance of NKG2D in tumor surveillance was demonstrated in 
various mouse models such as the TRAMP (transgenic adenocarcinoma of 
the mouse prostate) and Eµ-Myc mice models, which NKG2D deficiency led 
to more aggressive tumor development (Guerra et al., 2008; Raulet and 
Guerra, 2009). In this study, we have demonstrated for the first time that 










Materials and methods 
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Mice  
C57BL/6 and BALB/c mice were purchased from the Centre for animal 
resources at the National University of Singapore. Lox-stop-lox (LSL)-K-Ras 
G12D mice expressing an interferon (IFN)-inducible conditional oncogenic K-
ras allele from its endogenous promoter was crossed to Mx1-Cre transgenic 
mice (Jackson Laboratory, USA) to obtain double-transgenic LSL-K-Ras 
G12D+/-/Mx1-Cre+/– mice. For induction of Cre expression, 4- to7-week-old 
mice were injected intraperitoneally with 250 %g of polyinosinic:polycytidylic 
acid (poly I:C) (Sigma, Singapore) every other day for three doses. The mice 
were bred and housed as described in (Jamieson et al., 2002).  
 
Cell cultures 
SM1 cells were a breast tumor cell line derived from BALB/c mice (Miyamoto 
et al., 1990). Post-senescent fibroblast cells were generated from C57BL/6. 
BC2 cells were a B cell lymphoma cell line derived from Eµ-Myc mice 
(Corcoran et al., 1999). All cell lines were maintained in RPMI-1640 (Gibco, 
Singapore) supplemented with 5% heat-inactivated fetal bovine serum (FBS), 
20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 1.42 
μE L-glutamine, 1300 units/mL penicillin, 26 mg/mL streptomycin, 5.2 mg/mL 
gentamicin sulphate and 1.82  with 5% #-mercaptoethanol, unless otherwise 
specified. Cells were incubated at 37 °C in humidified 5% CO2 incubator with 
atmospheric oxygen (20% O2). 
 
Reagents 
Cytosine #-D-arabinofuranoside hydrochloride (Ara-C), Caffeine and dimethyl 
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sulfoxide (DMSO) were purchased from Sigma (Singapore). The ATM/ATR 
inhibitor CGK733, the growth factor inhibitors for PDGFR (platelet-derived 
growth factor receptor), FGF (fibroblast growth factor receptor)/VEGFR 
(vascular endothelial growth factor receptor), EGFR and IGFR (insulin-like 
growth factor receptor), Ras (farnesyl transferase) inhibitor FTI-277, MEK 
inhibitor U0126, and PI3 kinase inhibitor LY294002 were purchased from 
Calbiochem (Singapore). Recombinant EGF was purchased from Peprotech 
(USA). Enzyme phosphatidylinositol-specific phospholipase C (PI-PLC) was 
purchased from Sigma (Singapore). 
 
Treatments of cells 
For serum starvation experiments, post-senescent fibroblasts were cultured in 
0.1% FBS-supplemented medium for 72 hours. As a control, the fibroblasts 
were cultured in 10% FBS-supplemented medium for the same duration. 
Recombinant EGF (20 ng/mL) was added to the serum-starved cells for 
reconstitution. To block the growth factor receptors signaling, post-senescent 
fibroblasts were treated with different growth factor inhibitors (2 µM for all, 
except 1 µM for IGF). Fibroblasts were treated with FTI-277 (10 µM) for 18 
hours to inhibit Ras signaling. Transduced SM1 cells were treated with U0126 
(10 µM), LY294002 (10 µM), or the combination of the two drugs for 36 hours 
for inhibition of MEK, PI3K or both kinases. To inhibit ATM/ATR, SM1 cells 
were pre-incubated with CGK733 (10 µM), or Caffeine (10 mM) for 2 hours, 
before Ara-C (10 µM) treatment for 16 hours, which induces DNA damage. To 
cleave off the cell surface GPI-anchored Rae-1 proteins, cells were treated 
with PI-PLC according to manufacturer’s recommendations. In brief, 
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monolayers of cells at 60-70% confluency grown in 6-well plates were first 
washed in phospho-buffer saline (PBS) twice before treating with various 
amounts of PI-PLC (ranging from 0.01 to 0.2 units) in 300 µL PBS per well for 
20 minutes with gentle shaking at 4°C.  
 
Flow cytometry  
Cells were stained for different mouse NKG2D ligands using fluorescein-
conjugated Rae-1 (pan-specific) (R&D Systems, USA) and PE-conjugated 
Rae-1! and Rae-1" (eBioscience, USA) in a single-step staining, or Rae-
1&#!- (recognizes the conserved epitopes of Rae-1&, #, and !), Rae-1#"- 
(recognizes the conserved epitopes of Rae-1#, and "), Rae-1% and Mult1 
antibodies (R&D Systems, USA) followed by APC-coupled rat IgG-specific 
antibodies (eBioscience, USA) in a two-step staining. EGFR expression was 
verified by staining with goat anti-mouse EGFR antibody (eBioscience, USA) 
followed by Alexa Fluor 647-conjugated anti-goat antibodies (Invitrogen, 
Singapore). BrdU Flow kit (BD Pharmigen, USA) was used to stain BrdU 
incorporation into replicating nuclear DNA 75 minutes after pulsing the cells 
with 10 μM BrdU, according to manufacturer’s protocol. For cell cycle 
analysis, cells were harvested and fixed by dropwise addition of 70% ice-cold 
ethanol, and incubated on ice for half an hour before staining. After 
incubation, fixed cells were pelleted and stained with solution containing 50 
μg/ml propidium iodide (PI) and 5 mg/ml RNase A. Cell aggregates or 
doublets were gated out based on the width of PI fluorescence signal. 2 X 104 
events were acquired per analysis. NK cell population was identified as 
DX5+CD3- cells using mouse-specific APC-conjugated anti CD49b (clone 
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DX5) and FITC-conjugated anti CD3e (eBioscience, USA) antibodies. Myeloid 
tumor cells developed by LSL-K-ras G12D+/-/Mx1-Cre+/– mice were identified 
by Gr-1+CD11b+ populations using mouse specific Pacific Blue-conjugated 
anti mouse Gr-1 and PerCP-Cy5.5-conjugated anti mouse CD11b 
(eBioscience, USA) antibodies. Stained cells were analyzed by multicolor flow 
cytometry using a FACSCalibur, LSRFortessa cell analyzer (both BD 
Biosciences, Singapore), CyAn™ Flow Cytometer (Beckman Coulter, 
Singapore) and FlowJo. 8.8.7 (Treestar, USA).  
 
Constructs and transfection or transduction of cells 
Retroviral vectors of human H-Ras 12V, H-Ras 12V T35S, H-Ras 12V E37G, 
H-Ras 12V Y40C, K-Ras 12V, N-Ras 61K, B-Raf V600E and C-Raf 22W in 
pBabe-puromycin, pBbae-puromycin empty vector, MSCV-H-Ras 12V-IRES-
GFP and dominant negative H-Ras 17N in PCI mammalian expression vector 
were obtained from Addgene (USA). PCI empty vector was obtained by 
excising H-Ras 17N from NotI and PvuII sites, blunted and ligated. MSCV-
puromycin empty vector were obtained by excising c-Myc T58A from BglII and 
EcoRI sites, blunted and ligated. Empty vector pMSCV2.2-IRES-GFP proviral 
vector was gift of W. Sha, University of California, Berkeley. E7 and mouse 
cyclin D1 were subcloned adjacent to XhoI and NotI sites into MSCV2.2-
IRES-GFP. Retroviral supernatants were generated as described in 
(Diefenbach et al., 2003).  
 
LAK cell preparation and cytotoxicity assay 
Mouse NK cells were isolated from BALB/c mice spleens using EasySep® 
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Mouse NK Cell Enrichment Kit (Stem Cell Technology, Singapore) following 
manufacturer’s instructions. The NK cells were cultured for another 4 days in 
1000 units/mL recombinant human IL-2 to become lymphokine-activated killer 
(LAK) cells before co-incubation with target cells. The LAK cell purity was 
determined by flow cytometry to be greater than or equal to 90% of DX5+CD3- 
lymphocyte population at the end of the 4-day culture. CytoTox 96 cytotoxicity 
assay kit (Promega, Singapore) was used for SM1 cell cytotoxicity by LAK 
cells following manufacturer’s instructions. The cells were cultured at different 
effector to target cell ratios of 30:1, 10:1 3:1 and 1:1. NKG2D-blocking 
antibodies (eBioscience, clone MI6, USA) or IgG2a isotype control 
(eBioscience, USA) antibodies were used at 50 μg/mL. Effectors and target 
cells were allowed to co-culture for 4 hours before the supernatant was taken 
for cytotoxicity analysis.  
 
Quantitative real-time RT-PCR 
Total RNA was isolated using the RNeasy kit (Qiagen, Singapore). 2 tal R 
total RNA was reverse transcribed with random hexamers using a 
Transcriptor First Strand cDNA Synthesis Kit (Roche, Singapore). Each 
amplification mixture (25 μl) contained 50 ng of reverse transcribed RNA, 8 
μM forward primer, 8 μM reverse primer and 12.5 μl of iTaq SYBR Green 
Supermix with ROX (Bio-Rad, Singapore). PCRs were performed in triplicates 
using the ABI PRISM® 7700 Sequence Detection System (Applied 
Biosystems, Singapore). PCR thermocycling parameters were 50°C for 2 min, 
95°C for 3 min, and 40 cycles of 95°C for 15 sec and 60°C for 30 sec and 
72°C for 45 sec. All samples were normalized to the signal generated from 
! #'!
the housekeeping gene HPRT. The following primers were used: Hprt-5’: 
tgggaggccatcacattgt; Hprt-3’: gcttttccagtttcactaatgaca; Pan-Rae-1-5’: 
tggacactcacaagaccaatg; Pan-Rae-1-3’: cccaggtggcactaggagt; Samples 
prepared without reverse-transcription served as negative control templates.  
 
Western Blotting 
Cells were lysed using the radio-immunoprecipitation assay (RIPA) buffer 
containing 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40 
and 1% Sodium Deoxycholate. Protease Inhibitor Cocktail Set III (Merck, 
Singapore) and Phosphatase Inhibitor Cocktail Set V (Merck, Singapore) was 
added to the lysis buffer. 30 μg proteins were loaded per lane on a 15% 
reducing sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) gel. Proteins were transferred to a nitrocellulose membrane 
(Amersham, Singapore) and probed with phospho-"H2AX antibody following 
the instructions from Cell Signaling Technology (USA). Blots were probed for 
GAPDH (Sigma, Singapore) expression as loading controls. 
 
Microscopy 
Monolayers of H-Ras 12V-IRES-GFP or MSCV-IRES-GFP empty 
vector-overexpressing SM1 cells were grown overnight on cover slips 
pretreated with poly-lysine (Sigma, Singapore) and fixed according to 
manufacturer’s instructions (Millipore, Singapore). In brief, cells were washed 
with PBS and incubated in 80% methanol at -20 °C for 30 minutes followed by 
washing with PBS. Subsequently, the cells were treated with formamide 
(Sigma, Singapore) at room temperature then 75°C for 10 minutes before 
! #(!
chilled at 4°C immediately thereafter to denature the DNA. Cells were further 
washed in Tris-buffer saline (TBS) before enzyme treatments. All cells were 
treated with 2 mg/mL RNase A (Sigma, Singapore) for 30 min at 37°C to 
remove RNA. As a specific negative control for single-stranded DNA (ssDNA) 
stainings, cells were incubated with additional 1000 units/mL S1 nuclease 
(Fermentas, USA) that digests ssDNA for 1 hour at 37°C. As a more general 
negative control, cells were incubated with 100 units/mL DNase (promega, 
Singapore) that digest DNA indiscriminately for 1 hour at 37°C. After washing 
with PBS, cells treated with only RNase, both RNase and S1 nuclease or 
DNase were stained with antibodies specific for ssDNA (clone F7-26, 
Millipore, Singapore), followed by Cy3-conjugated anti-mouse IgM antibodies 
(Millipore, Singapore). Slides were finally stained with DNA fluorochrome 4',6-
diamidino-2-phenylindole (DAPI) (0.05 mg/mL in PBS) for 10 min. Slides were 
washed in PBS before mounting with Dako fluorescent mounting medium 
(Dako, UK). Images were taken on a confocal TCS SP5 (Leica, Singapore). 












3.1. EGF-dependent NKG2D ligand expression in fibroblasts 
We previously observed upregulation of NKG2D ligands in response to 
DNA damage (Gasser et al., 2005). However, when we established fibroblasts 
from mice, we consistently observed upregulation of NKG2D ligands in 
presence of DNA damage response (DDR) inhibitors or in 3% oxygen, which 
only minimally activates the DDR (Di Micco et al., 2008). In addition, 
conditional deletion of ATR gene leading to the blocking of the DNA damage 
pathways in fibroblasts could only result in a partial suppression of NKG2D 
ligand expression (Gasser et al., 2005). All these suggested that NKG2D 
ligands could be induced by DDR-independent pathways.  
Growth factors are key components in serum that induce proliferation 
by activating Ras (Bjare, 1992; Karnoub and Weinberg, 2008). To investigate 
the role of growth factors in the spontaneous upregulation of NKG2D ligands, 
we starved NKG2D ligand-positive fibroblasts of serum. Serum starvation of 
fibroblasts for 3 days resulted in G1 cell cycle arrest in fibroblasts, as we 
observed a much greater G1 population (60.3% vs 37.6%) and reduced 
population in S-phase (16.2% vs 37.9%) in the serum-starved cells as 
compared to the control cells (Fig. 7A). Correspondingly, serum-starved 
fibroblasts showed significantly reduced levels of NKG2D ligands Rae-1 and 
Mult1 expression (Fig. 7B). Our data suggest that serum-induced signal, likely 
















Figure 7. NKG2D ligand expression levels are reduced upon serum 
starvation. A, Cell cycle analysis on fibroblasts grown in either 10% FBS- 
(left) or 0.1% FBS-containing medium (right) for 66 hours. Red, blue and 
green lines indicate cell populations in G1-, S- and G2-phase respectively.  B, 
Analysis of NKG2D ligand expression levels on fibroblasts grown in either 
0.1% FBS- (red lines) or 10% FBS- containing medium (blue lines) for 66 
hours. Filled histograms and dashed lines represent isotype controls for 
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Serum is a complex mixture of constituents. To show that expression of 
NKG2D ligands depends on growth factors more conclusively, we treated 
fibroblasts with different chemical inhibitors for growth factors. We observed 
that inhibition of EGFR induced cell cycle arrest at the G1/S check-point (Fig. 
8A), and reduced NKG2D ligand Rae-1, but not Mult1 levels (Fig. 8B). In 
further support of a role of EGF in the spontaneous upregulation of NKG2D 
ligands, we found that fibroblasts express EGFR at the cell surface (Fig. 8C). 
The reduction in Rae-1 expression levels by EGF inhibition for 18 hours was 
comparable to that of serum starvation for 3 days. Nevertheless, EGFR 
inhibition did not downregulate Mult1 level as did prolonged serum starvation, 
suggesting differences in response time or regulatory mechanisms of the 
different ligands.  
It is worth to mention that inhibition of other growth factor receptors on 
fibroblasts like IGFR, PDGFR and FGFR/ VEGFR had little or no effects on 
the ligands (Supplementary Fig. 1). As these growth factors were reported to 
trigger similar signals as EGF, it is, possible that fibroblasts did not respond to 
these growth factors due to absence of the respective receptors on the cell 
surface or other components of the signaling pathways. Alternatively, it is 
possible that the growth factors act in a redundant fashion. 
! $#!
 
Figure 8. Chemical inhibition of EGFR impairs NKG2D ligand expression 
levels on fibroblasts. A, Cell cycle analysis on fibroblasts treated with DMSO 
(left) or 2 asts tr inhibitor (right) for 18 hours. Red, blue and green lines 
indicate cell populations in G1-, S- and G2-phase respectively. B, NKG2D 
ligand analysis on fibroblasts treated with 2 μM EGFR inhibitor (red lines) or 
DMSO (blue lines) for 18 hours. Filled histograms and dashed lines represent 
isotype controls for DMSO and inhibitor-treated fibroblasts respectively. C, 
EGFR was expressed on fibroblasts. Cells were stained with 5 µg/mL anti-
mouse EGFR antibody followed by 2 µg/mL Alexa Fluor 647 rabbit anti-goat 
IgG (black line) compared to the cells stained with 2 µg/mL Alexa Fluor 647 
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Furthermore, addition of recombinant murine EGF restored cellular 
proliferation (Fig. 9A) and NKG2D ligand Rae-1 expression levels (Fig. 9B) in 
fibroblasts cultured in serum-starved conditions by 18 hours. These data 
suggested that EGF, among the complex constituents of FBS, provided key 
signals for proliferation and NKG2D ligand Rae-1 induction. On the contrary, 
EGF did not induce Mult1. This further supports the argument that Mult1 and 
Rae-1 have different regulatory mechanisms and/or kinetics. 
 
Figure 9. Recombinant EGF restores NKG2D ligand expression levels on 
serum-starved fibroblasts. A, Cell cycle analysis on fibroblasts grown in 
0.1% FBS-containing medium for 3 days, with (left) or without (right) addition 
of 20 ng/μL recombinant EGF 18 hours before staining. Red, blue and green 
lines indicate cell populations in G1-, S- and G2-phase respectively. B, 
NKG2D ligand analysis on fibroblasts grown in 0.1% FBS-containing medium 
for 3 days, with (red lines) or without (blue lines) addition of 20 ng/NKG2D 
ligand analysis on fibroblasts grown inIsotype controls of fibroblasts grown in 
0.1% FBS-supplemented medium with (dashed lines) or without (filled 
histograms) EGF are shown. 
B 
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3.2. H-Ras12V induces Rae-1 expression  
Stimulation of cells with EGFR results in activation of Ras (Avraham 
and Yarden, 2011; Kamata and Feramisco, 1984). Furthermore, earlier 
research has shown that activation of H-Ras can induce tumorigenesis 
(Karnoub and Weinberg, 2008), could also result in NK cell-mediated lysis 
(Trimble et al., 1986). Given the role of NKG2D in immunosurveillance, we 
investigated the role of Ras activation in regulating NKG2D ligands.  
We transduced a murine breast tumor cell line SM1, which expresses 
relatively low levels of NKG2D ligands with different oncogenic forms of Ras. 
Constitutively active H-Ras 12V induced significant upregulation of epitopes 
for Rae-1&#!, Rae-1#", but not Rae-1!, Rae-1" or Rae-1$-specific antibodies 
suggesting H-Ras 12V induced the expression of NKG2D ligand Rae-1 
isoforms & and # (Fig. 10A and B). More strikingly, Rae-1# (stained by Rae-
1#"-specific antibodies), which was not expressed in control cells, was highly 
induced by H-Ras 12V expression (Fig. 10A). Hence, our data showed that H-
Ras 12V could induce Rae-1# de novo, besides possibly enhancing Rae-1& 
expression. Intriguingly, other oncogenic Ras like N-Ras 61K and K-Ras 12V 
were unable to induced Rae-1#, and only weakly induced Rae-1& expression 
in SM1 (Fig. 10A), implying distinctive roles of Ras isoforms in NKG2D ligand 
Rae-1 induction. None of the Ras oncogenes did induce Mult1 (Fig. 10A). 
! $&!
 
Figure 10. H-Ras 12V, and to a lesser extent N-Ras 61K and K-Ras 12V 
expression upregulates NKG2D ligands Rae-1 (but not Mult1) in SM1 
cells. SM1 cells were transduced with pBabe-H-Ras 12V (top, red lines), 
pBabe-N-Ras 61K (middle, red lines), pBabe-K-Ras 12V (bottom, red lines) or 
the pBabe-puromycin empty vector (blue lines), and selected for puromycin 
resistance. Cells were stained for indicated NKG2D ligand expression 5-12 
days post-transduction. Filled histograms and dashed lines indicate isotype 
controls for pBabe-puromycin and Ras-transduced SM1 cells. B, Rae-1 %, " 
and $ are not expressed on control SM1 cells (blue lines), nor they are 
inducible by H-Ras 12V expression (red lines). Filled histograms and dashed 




























We also transduced other murine cell lines with the different isoforms 
of Ras. We observed upregulation of Rae-1 isoforms in both lymphoma cell 
line BC2 and fibroblasts upon Ras activation (Fig. 11 and 12). Consistent with 
the observations in SM1 cells, H-Ras 12V induced, but to a lesser extent, 
epitopes for Rae-1&#! and Rae-1#"-specific antibodies in BC2 cells and 
fibroblasts (Fig. 11 and 12). N-Ras 61K and K-Ras 12V only showed marginal 
induction of Rae-1&#!, but not Rae-1#" (Fig. 11 and 12). All three Ras 
isoforms failed to induce Mult1 expression in either BC2 cells or fibroblasts 
(Fig. 11 and 12). These data indicate that the regulation of Rae-1 ligands by 




Figure 11. H-Ras 12V, and to a lesser extent N-Ras 61K and K-Ras 12V 
expression upregulates NKG2D ligands Rae-1 (but not Mult1) in BC2 
cells. BC2 cells were transduced with MSCV-H-Ras 12V-IRES-GFP (top, red 
lines), MSCV-N-Ras 61K-IRES-GFP (middle, red lines), MSCV-K-Ras 12V-
IRES-GFP (bottom, red lines) or the MSCV-IRES-GFP empty vector (blue 
lines). Cells were stained for indicated NKG2D ligand expression 12 days 
post-transduction, and the analysis was based on GFP+ cells. Filled 
histograms and dashed lines indicate isotype controls for GFP empty vector- 

















Figure 12. H-Ras 12V, and to a lesser extent N-Ras 61K and K-Ras 12V 
expression upregulates NKG2D ligands Rae-1 (but not Mult1) in 
fibroblasts. Fibroblasts were transduced with pBabe-H-Ras 12V (top, red 
lines), pBabe-N-Ras 61K (middle, red lines), pBabe-K-Ras 12V (bottom, red 
lines) or the pBabe-puromycin empty vector (blue lines), and selected for 
puromycin resistance. Cells were stained for indicated NKG2D ligand 
expression 5-12 days post-transduction. Filled histograms and dashed lines 
















  We checked the induction of Rae-1 in SM1 at the transcriptional level, 
using primers that amplify all the known Rae-1 isoforms. We observed a 
significant overall increase of Rae-1 mRNA as a result of H-Ras 12V 
overexpression (Fig. 13). Nevertheless, the increase of Rae-1 transcript was 
only two-fold (Fig. 13), which did not correspond to the strong induction at the 
cell surface level (Fig. 10A), suggesting the existence of post-transcriptional 




Figure 13. H-Ras 12V induces Rae-1 transcription. H-Ras 12V expression 
upregulated Rae-1 transcripts (filled bar) compared to the control (open bar). 
The Rae-1 primers could amplify all Rae-1 isoforms. Analysis was based on 
the cells transuduced with H-Ras 12V or control vector 3 days to 3 weeks 
post-transduction.  No significant variations in the upregulation of Rae-1 
transcript were observed for cells transduced for different periods of time. 
Rae-1 fold increase was normalized against GFP expression.  Data represent 
means + s.d., n = 5 independent experiments. Paried-Student’s t-test was 
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 In addition to the gain-of-function studies, we have also conducted 
loss-of-function experiments to examine the role of Ras inhibition in regulation 
of NKG2D ligands. We treated fibroblasts expressing high levels of NKG2D 
ligands with FTI-277, a farnesyl transferase inhibitor that inhibits Ras 
membrane localization, and thereby its function (Lerner et al., 1995). We 
observed both reduced Rae-1&#! and Rae-1#", but not Mult1 expression 
levels in these cells (Fig. 14A). As a more specific approach we 
overexpressed a dominant-negative form of Ras, H-Ras 17N, and similar 
results were observed. These data indicate that the maintenance of Rae-1, 
but not Mult1, in fibroblasts depends on H-Ras activity (Fig. 14B).   
To examine if the effects of Ras inhibition on Rae-1 downregulation 
were associated with lack of proliferation, we stained H-Ras 17N-transfected 
cells with BrdU to analyze their proliferation by BrdU incorporation into DNA. 
Surprisingly, we could not observe any difference in proliferation between the 
control vector- and H-Ras 17N-transfected cells (Fig. 14C), even though we 
based our analysis on GFP-positive populations; an indication of the cells 
expressing the H-Ras 17N construct. These data suggest that the NKG2D 
ligand Rae-1 expression might not be strictly dependent on proliferation, but 




Figure 14. NKG2D ligand expression levels are reduced by Ras 
inhibition. A, Fibroblasts were treated with FTI-277, a farnesyl transferase 
inhibitor (10 µM, red lines) or DMSO (blue lines) for 18 hours. Filled 
histograms and dashed lines represent isotype controls of DMSO- or FTI-277-
treated cells. B, Dominant-negative Ras expression inhibits NKG2D ligand 
expression in fibroblasts. Fibroblasts were transfected with pCI-H-Ras 17N-
EGFP (red lines) or pCI-EGFP empty vector (blue lines). 96 hours after 
transfection GFP+ cells were analyzed for NKG2D ligand expression. Filled 
histograms and dashed lines show isotype controls of empty vector- and pCI-
H-Ras 17N-transfected fibroblasts. C, H-Ras 17N expression does not affect 
proliferation in fibroblasts. Fibroblasts were transfected with pCI-EGFP empty 
vector (left panels) or pCI-H-Ras 17N-EGFP (right panels). BrdU incorporation 
of the cells pulsed with 10 µM BrdU 75 minutes prior to staining were 
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3.3. H-Ras 12V induces expression of a PI-PLC-resistant Rae-1& isoform 
Rae-1 proteins are GPI-anchored proteins on cell membranes 
(Cerwenka et al., 2000; Nomura et al., 1996b). To our surprise, when we 
treated H-Ras 12V-transduced and control cells with PI-PLC that cleaves off 
most of the GPI-anchored proteins, we could still observe significant 
expression of Rae-1& (by Rae-1&#!-specific antibodies) in H-Ras 12V-
overexpressing SM1, but not in control cells at saturating PI-PLC 
concentrations (0.1 units per 300 µL, i.e., 0.33 units/mL, Fig. 15). On the other 
hand, Rae-1# expression (by Rae-1#"-specific antibodies) was undetected 
after PI-PLC treatment in both H-Ras 12V or control vector-transduced SM1 
(Fig. 15). Thus, we speculated that H-Ras 12V could induce a PI-PLC-
resistant form of Rae-1α isoform, or a transmembrane domain-containing 





Figure 15. H-Ras 12V induces PI-PLC-resistant Rae-1α expression. SM1 
transduced with MSCV-IRES-GFP empty vector control (left panels) or H-Ras 
12V (right panels) were treated with increasing amounts of PI-PLC (red lines, 
with units indicated on the left) or PBS (blue lines) in 300 µL PBS at 4°C for 
20 minutes. Gray dashed lines mark the minimal level of Rae-1&#! staining. 
Filled histograms and dashed lines represent isotype controls for empty 

















3.4. H-Ras 12V induced Rae-1 expression is independent of DDR  
 We have previously shown that DNA damage induced the expression 
of NKG2D ligands and might contribute to the constitutive expression of 
NKG2D ligands on many tumor cells (Gasser et al., 2005). Recent data 
suggested that DNA damage in tumor cells is caused by the activation of 
oncogenes (Bartkova et al., 2006; Di Micco et al., 2006). As a result, we 
wanted to investigate whether oncogene activation could induce NKG2D 
ligands via DDR.  
We analyzed SM1 cells overexpressing different oncogenes or controls 
for the DNA damage marker phospho-"H2AX. Not surprisingly, as a tumor cell 
line, SM1 (MSCV-GFP and MSCV-puromycin empty vector-transduced 
controls) constitutively expressed phospho-"H2AX (Fig. 16A), indicating 
persistent DDR in these cells. Intriguing, overexpression of some oncogenes 
increased the phospho-"H2AX levels while others did not. For instance, K-
Ras 12V, E7 and cyclin D1 seemed to increase the phospho-"H2AX levels, 
whereas H-Ras 12V, N-Ras 61K and c-Myc T58A did not (Fig. 16A). 
While oncogenic H-Ras strongly induced NKG2D ligands Rae-1 (Fig. 
10A), other oncogenes like c-MycT58A, E7 and cyclinD1 did not induce Rae-1 
or Mult1 expression (Fig. 16B). Taken together, these data suggest that not all 
oncogenes could induce Rae-1 expression and there is no linear correlation 
between oncogene-induced DDR and NKG2D ligand expression. In other 
words, the H-Ras 12V-induced Rae-1 expression was most likely to be 





Figure 16. Oncogene-induced DDR does not linearly correspond with 
upregulation of NKG2D ligands. A, Immunoblot analysis of phospho-"-
H2AX on lysates from SM1 cells overexpressing oncogenes like H-Ras 12V, 
N-Ras 61K, K-Ras 12V, E7, cyclinD1, c-Myc T58A or their respective controls 
(MSCV-IRES-GFP for all except c-Myc T58A, and MSCV-puromycin for c-Myc 
T58A) for 10 days and selected based on GFP expression or puromycin 
resistance. GAPDH were probed and served as loading controls. B, NKG2D 
ligand analysis on SM1 cells (from A) overexpressing c-Myc T58A, E7 or 
cyclinD1 (red lines) or empty control vectors (blue lines). Filled histograms 




























We have previously observed that DNA damage-induced NKG2D ligand 
upregulation depends on the DDR kinases ATM/ATR (Gasser et al., 2005). In 
accordance, SM1 cells treated with the DNA damaging drug Ara-C induced 
NKG2D ligands (Fig. 17), suggesting the existence of functional DDR pathway 
in these cells. To reaffirm such induction depended on ATM/ATR, we treated 
the cells with CGK733 or Caffeine, different chemical inhibitors of ATM/ATR. 
Expectedly, pretreatment of both drugs abolished the DNA-damage induced 
NKG2D ligand upregulation (Fig. 17).  
 
Figure 17. DNA damage-induced NKG2D ligand upregulation depends 
on ATM/ATR. SM1 cells were pretreated with 10 µM CGK733 (top) or 10 mM 
Caffeine (bottom) for 2 hours, followed by treatment of 10 µM Ara-C (red 
lines) or DMSO (blue lines) for 16 hours.  Black lines represent NKG2D ligand 
expression levels on Ara-C-treated cells without inhibitor pre-treatment. Filled 
histograms show isotyoe controls for DMSO treated cells, whereas dashed 
and dotted lines represent isotype controls for Ara-C treated cells with or 


















To directly test the role of DDR in Ras-induced NKG2D ligand 
upreguation, H-Ras 12V- or control- transduced SM1 cells were treated with 
the ATM/ATR inhibitors CGK733 or Caffeine to the DDR. Blocking of ATM 
and ATR did not impair Ras-induced NKG2D ligand expression (Fig. 18). 
Taken together, our data suggest that H-Ras 12V induced NKG2D ligands 




Figure 18. H-Ras 12V-induced NKG2D ligand expression does not 
depend on DDR kinases ATM/ATR. Inhibition of ATM/ATR by CGK733 (10 
µM) or Caffeine (10 mM) did not reduce NKG2D ligand levels on H-Ras 12V-
transduced SM1 cells (red lines) as compared to DMSO controls (blue lines). 
Black lines depict basal NKG2D ligand expression on empty vector-
transduced SM1. Isotype controls for H-Ras 12V-overexpressing SM1 treated 
with DMSO (filled histograms) or inhibitors (dashed lines) and control SM1 

















 Although H-Ras 12V and DDR signal through distinct pathways to 
induce NKG2D ligands, the two agents may have addictive effects. DDR 
could induce NKG2D ligands further in H-Ras 12V-transduced SM1 cells and 
the overall ligand levels were higher than those expressed as a result of DDR 




Figure 19. H-Ras 12V and DDR have addictive effects in inducing NKG2D 
ligands. SM1 cells were transduced with pBabe-puromycin empty vector (top) 
or H-Ras 12V (bottom) and further treated with 10 µM Ara-C (red lines) or 
DMSO (blue lines) for 18 hours. Filled histograms and dashed lines represent 















3.5. Induction of NKG2D ligands depends on multiple Ras-induced pathways 
Ras activates multiple downstream pathways, including Raf/ERK/MEK, 
PI3 kinase and Ral GTPase pathways (Downward, 2003). Overexpression of 
oncogenic B-Raf V600E was able to induce NKG2D ligand Rae-1& (stained 
by Rae-1&#!-specific antibody), but not Rae-1# (stained by Rae-1#"-specific 
antibody) expression on SM1 cells (Fig. 20). Furthermore, the Rae-1& 
induction by B-Raf V600E was not as strong as compared to that of H-Ras 
12V (Fig. 20 and Fig. 10A). On the contrary, oncogenic C-Raf 22W was not 
able to induce NKG2D ligands (Fig. 20). Like H-Ras 12V, neither B-Raf 
V600E nor C-Raf 22W induced Mult1 expression. Collectively, these data 
imply that Raf activation contributes to Ras-induced NKG2D ligand Rae-1 
expression.  
Raf phosphorylates and activates MEK. Inhibition of MEK (by U0126) 
led to a partial reduction of H-Ras 12V-induced Rae-1 upregulation (Fig. 21). 
Likewise, inhibiting PI3K (by LY294002), another signaling arm downstream 
of activated Ras resulted in a modest reduction of Rae-1 expression (Fig. 21). 
Simultaneous inhibition of both pathways has additive effects, which greatly 
diminished the Ras-induced Rae-1 upregulation (Fig. 21).  Hence, it is most 
likely that both Raf/MEK and PI3K pathways are required for the Ras-induced 
Rae-1 upregulation (Fig. 21).  
Intriguingly, inhibition of MEK or PI3K individually did not affect Mult1 
expression in H-Ras 12V-overexpressing SM1 cells, but prolonged combined 
inhibition (for 36 hours) decreased Mult1 expression level in these cells below 
the baseline levels as in the control cells. This is in contrast to our 
observations earlier (Fig. 14A and B), in which we showed that inhibition of 
! &+!
Ras signaling by either chemical or genetic means did not reduce Mult1 levels 
in fibroblasts. It is possible that MEK and PI3K are activated by other signals 
than Ras in fibroblasts. Alternatively, it is could be that tissue and/or strain 
difference are responsible to the difference. Further studies are required for a 
better understanding of Mult1 regulation.  
 
 
Figure 20. Oncogenic B-Raf (but not C-Raf) expression upregulates 
NKG2D ligands in SM1 cells. SM1 cells were transduced with pBabe-B-Raf 
V600E and pBabe-C-Raf 22W (red lines) as compared to the pBabe-
puromycin empty vector (blue lines). The cells were selected based on 
puromycin resistance and analyzed 5-12 days post-transduction. Filled 
histograms and dashed lines represent isotype controls for empty vector- and 
























Figure 21. MEK and PI3K are required for Ras-induced NKG2D ligand 
upregulation. SM1 cells were treated with MEK inhibitor U0126 (top, red 
lines), PI3K inhibitor LY294002 (middle, red lines), combination of the two 
(bottom, red lines) or DMSO (blue lines) for 36 hours. Black lines represent 
NKG2D ligand expression levels on pBabe-puromycin-transduced cells. 
Isotype controls for H-Ras12V-SM1 treated with DMSO (filled histograms) or 
inhibitors (dashed lines) and control SM1 (dotted lines) were shown. 
 
While H-Ras 12V activates Raf, RalGEF and PI3K, mutant forms of H-
Ras 12V such as T35S, E37G or Y40C are capable of activating only one of 
the downstream Raf, RalGEF or PI3K pathways. Interestingly, all three H-Ras 
12V mutants failed to induce NKG2D ligands in SM1 cells (Fig. 22). This 
agrees with the previous findings (Fig. 20 and 21) that multiple arms 
LY294002 



















downstream of Ras are required and they cooperate in inducing NKG2D 
ligand Rae-1 expression.  
 
 
Figure 22. Raf, RalGEF or PI3K signals, downstream of Ras, are not 
sufficient to upregulate NKG2D ligand expression. SM1 were transduced 
with pBabe-H-Ras 12V with additional mutations -T35S, E37G or Y40C- (red 
lines) or pBabe-puromycin empty vector (blue lines). Black lines represent 
NKG2D ligand levels on pBabe-H-Ras 12V-transduced cells. Filled 
histograms show isotype control of control SM1. Dashed lines and dotted 
lines show isotype control of SM1 transduced with H-Ras 12V with or without 
additional mutations. 
 

























3.6. H-Ras 12V expression enhances tumor cell sensitivity to LAK cell 
cytotoxicity  
Upregulation of NKG2D ligands renders cells more sensitive to NK cell-
mediated lysis (Jamieson et al., 2002). As expected, H-Ras 12V 
overexpression rendered SM1 targets more sensitive to cytotoxicity mediated 
by LAKs (Fig. 23). Notably, even at low effector to target ratios, H-Ras 12V-
overexpressing cells exhibited 50% greater LAK cell-mediated lysis compared 
to control cells (Fig. 23). Lysis was inhibited by NKG2D blocking antibody, 
indicating that upregulated ligands increased lysis (Fig. 23). The complete 
blocking suggested that increased sensitivity of H-Ras 12V-transduced cells 




Figure 23. H-Ras 12V expression enhances LAK cell cytotoxicity via 
NKG2D ligand-receptor interaction. H-Ras 12V or pBabe-puromycin empty 
vector-overexpressing SM1 cells were incubated with LAK cells for 4 hours 
with NKG2D blocking antibodies (orange lines with open circles and cyan 
lines with open triangles respectively) or IgG2a isotype control antibodies (red 
lines with filled circles and blue lines with filled triangles) at different E:T ratios 
30:1, 10:1, 3:1 and 1:1. LAK cells showed enhanced killing towards H-Ras 
12V-overexpressing SM1 than control. The difference in cytotoxicity was 
diminished by NKG2D blocking. Results shown were representative of 3 
similar experiments. 
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3.7. H-Ras 12V expression induces accumulation of cytoplasmic ssDNA 
 Recently, we found that DNA damage led to the accumulation of 
cytoplasmic DNA, and the activation of DNA sensors (Lam, et al. submitted). 
Interestingly, we observed cytoplasmic ssDNA in H-Ras 12V overexpressing 
cells but not in the controls when we stained cells with antibodies specific for 
ssDNA (Fig. 24). To determine the specificity of DNA staining, we pretreated 
the cells with the ssDNA-specific S1 nuclease or DNase that digests total 
DNA before staining (Suzuki et al., 1997; Yang et al., 2007). Accordingly, we 
observed absence of staining of cytoplasmic ssDNA after S1 nuclease or 
DNase digest, confirming the specificity of the staining (Fig. 24). Hence, our 
preliminary data suggest the possibility that H-Ras 12V may upregulate 
NKG2D ligand expression by inducing the accumulation of cytoplamic DNA by 
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3.8. Effects of K-Ras G12D on NKG2D ligands in vivo  
 To study the role of oncogenic Ras in tumor surveillance in vivo, we 
used K-Ras G12D transgenic mice. K-Ras was shown to have the highest 
mutation frequencies among all the Ras mutations (approximately 85%) in 
cancer patient samples (Lau and Haigis, 2009).  
 Lox-stop-lox (LSL)-K-Ras G12D mice expressing an IFN-inducible 
conditional oncogenic K-Ras allele from its endogenous promoter were 
crossed to interferon-responsive Mx1-Cre transgenic mice to obtain double-
transgenic LSL-K-Ras G12D+/-/Mx1-Cre+/– mice (Braun et al., 2004). 
Therefore, these mice do not express oncogenic K-Ras unless administrated 
with drugs inducing type I interferons. For induction of Cre expression, and 
subsequent expression of oncogenic K-Ras, 4- to 7-week-old mice were 
injected intraperitoneally with 250 %g of poly I:C every other day for a total of 
three doses. Total blood (after red blood cell lysis) was analyzed for tumor 
burden 4 weeks post-injection, and Gr1+CD11b+ populations were regarded 
as tumor cells (Braun et al., 2004). 
Evidently, LSL-K-Ras G12D+/-/Mx1-Cre+/– mice injected with poly I:C 
had massive proliferation of Gr1+CD11b+ populations as compared to their 
wild-type littermates (Fig. 25A). Subsequently, we analyzed NKG2D ligand 
expression based on the tumor cells using anti pan-Rae-1 antibody that 
recognizes all Rae-1 isoforms. No staining for Rae-1 was observed in either 
Gr1+CD11b+ tumor cells or normal adult cells (Fig. 25B). This may indicate 
that K-Ras G12D does not induce NKG2D ligands in vivo in myeloid cells or 
that NKG2D-positive cells are lysed by immune cells. To distinguish the two 





Figure 25. LSL-K-Ras G12D+/-/Mx1-Cre+/– mice develop myeloid 
proliferative disease (MPD), but the tumor cells do not express Rae-1. A, 
4-7 weeks old LSL-K-Ras G12D+/-/Mx1-Cre+/– mice treated with 250 ng poly 
I:C for 3 dosage every other day developed MPD 4 weeks post-injection. The 
myeloid tumor cells were identified as Gr1+CD11b+ populations. Data shown 
were representative of more than 5 mice for both LSL-K-Ras G12D+/-/Mx1-
Cre+/– and wide-type mice. B, Gr1+CD11b+ tumor cells from LSL-K-Ras 
G12D+/-/Mx1-Cre+/– mice did not express NKG2D ligand Rae-1 (blue) as 
























 In the present study, we have shown that deregulated proliferation 
induced by EGFR and oncogenic Ras that are often associated with 
tumorigenesis (Karnoub and Weinberg, 2008; Mendelsohn and Baselga, 
2000) could also lead to NKG2D ligand Rae-1, but not Mult1 upregulation. In 
this way, NKG2D ligand Rae-1 may create a barrier against the initial events 
of tumor development. The fact that not all oncogenes promoting proliferation 
(e.g. c-Myc T58A, E7 and cyclin D1) could induce NKG2D ligands, highlights 
that the strong NKG2D ligand inducer H-Ras 12V can activate the immune 
system potently.  
Intriguingly, other oncogenic Ras isoforms K-Ras and N-Ras were not 
efficient at inducing Rae-1. Unfortunately, little was known about the 
differences in signaling among the Ras isoforms, besides their distinctive 
expression patterns at cellular and subcelluar levels, and their abilities to 
induce differentiation and apoptosis (Karnoub and Weinberg, 2008; Lau and 
Haigis, 2009). Future studies are required to address these differences in 
Rae-1 regulation. One confounding issue in our study could be that SM1 cells 
we used for experiments had an inherent activating K-Ras mutation 
(Miyamoto et al., 1990). A gain-of function experiment with K-Ras 12V was 
not feasible in SM1, and we will have to address the role of endogenous K-
Ras by loss-of-function experiments.  
Oncogene activation and replicative stress result in DDR (Di Micco et 
al., 2006), which was shown to upregulate NKG2D ligands (Gasser et al., 
2005). However, the DDR did not cause the spontaneous expression of 
NKG2D ligands in primary fibroblasts as on SM1 cells, and we show here that 
Ras activation may be partially responsible to this induction. H-Ras 12V 
! '"!
induced Rae-1 via a novel pathway that was different from the DDR, since 
inhibition of DDR kinases ATM/ATR did not downregulate NKG2D ligands in 
H-Ras 12V-transduced cells. Besides, Rae-1# strongly induced by H-Ras 12V 
was minimally induced by DDR. Moreover, we observed no correlation 
between DNA damage and NKG2D ligand expression in cells expressing 
different oncogenes.  
The oncogenic H-Ras-induced Rae-1 expression depended on multiple 
downstream effectors pathways, suggesting that a Ras-specific signaling 
pathway induces NKG2D ligands rather than DDR. Deregulation of a single 
Ras effector pathway was not sufficient to induce Rae-1 expression, 
suggesting that the concerted activation of most Ras-induced effectors 
pathways collectively regulate Rae-1 expression. Among them, Raf/MEK and 
PI3K pathways appear to play crucial roles. Oncogenic Ras, but not other 
downstream targets with the exception of B-Raf, was able to transform cells, 
hence immunosurveillance may focus to monitor the activity of genes capable 
to induce transformation. 
Oncogenic H-Ras induction of Rae-1 might be regulated post-
transcriptionally, as the mRNA and cell surface level induction did not 
correlate. H-Ras 12V may also regulate Rae-1 expression through post-
translational mechanisms. Interestingly, H-Ras 12V-induced the expression of 
PI-PLC resistant Rae-1!, providing further evidence for the existence of post-
translational regulation, as the conventional Rae-1! isoform is GPI-anchored 
to plasma membranes is cleaved by PI-PLC. 
We observed inconsistent results for Mult1 induction by H-Ras 12V, 
suggesting that additional mechanism regulating Mult1 expression. Mult1 was 
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shown to be ubiquitinylated on lysines in the cytoplasmic tail, which induced 
subsequent lysosomal degradation (Nice et al., 2009). Heat shock and 
ultraviolet irradiation could signal for reduced Mult1 ubiquitination and 
degradation (Nice et al., 2009). Hence, the lysosomal degradation pathway 
may be deregulated in H-Ras 12V-transduced cells.  
NKG2D-deficient mice were shown to be defective in tumor 
surveillance in models of spontaneous malignancy (Guerra et al., 2008). Here 
we show that oncogenic H-Ras induced Rae-1 upregulation, rendering cells 
more sensitive to LAK-mediated lysis. Coincidentally, earlier research has 
shown that by inducing a single oncogene of mutant H-Ras, it could lead to a 
murine fibroblast cell line C3H 10T1/2 being more susceptible to NK cell-
mediated lysis (Trimble et al., 1986), but not cytotoxic T lymphocytes or 
activated macrophages (Johnson et al., 1987). While our data agree with the 
previous findings, we have further demonstrated the mechanism in the other 
facet of H-Ras 12V activation in immune tumor surveillance. 
H-Ras 12V oncogene was shown to induce senescence via DDR in 
normal human cells, which sets up a barrier for tumorigenesis (Di Micco et al., 
2006). Loss of DDR genes such as Chk2, ATM or p53 promotes cells to 
escape oncogene-induced senescence (OIS) and promotes tumor 
development (Di Micco et al., 2008). Nevertheless, we did not observe 
senescence in the murine tumor cell line SM1 when we overexpressed H-Ras 
12V. It is possible that these tumor cells have already mutated or deleted 
some of the genes in the pathway leading to senescence. Nevertheless, we 
could still observe DDR in these cells, as shown by Ara-C-induced NKG2D 
ligands. More strikingly, despite the lack of senescence, the cells upregulate 
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NKG2D ligands in response to H-Ras activation, leading to innate immune 
response. Therefore, it is likely that H-Ras 12V triggers an immune response 
even after senescence has been compromised, thereby, creating an 
additional barrier to tumorigenesis.  
Besides inducing NKG2D ligands Rae-1, our preliminary data showed 
that H-Ras 12V could also induce cytoplasmic ssDNA, possibly another 
means of alerting the immue system. Usually part of a viral response, the 
sensing of cytoplasmic DNA triggers TANK-binding kinase 1 (TBK1) and 
IRF3-dependent type I interferon and cytokine responses (Honda and 
Taniguchi, 2006; Takaoka et al., 2007). Our data suggest that the sensing of 
cytoplasmic DNA probably also plays a novel role in tumor surveillance. 
Certainly, further experiments need to be performed for a more 
comprehensive and in-depth analysis on the role of cytoplasmic DNA in tumor 
surveillance. For instance, whether H-Ras 12V can induce double-stranded 
DNA (dsDNA) still needs to be elucidated. More importantly, functional 
significance of H-Ras 12V-induced cytoplasmic DNA needs to be addressed. 
Finally, we studied the in vivo relevance of Ras activation in 
immunosurveillance. We did not observe Rae-1 in tumor cells arising from K-
Ras G12D transgenic mice. K-Ras G12D may not induce NKG2D ligands in 
vivo in myeloid cells or it is possible that NKG2D-positive cells are lysed by 
immune cells. To address the role of Ras-induced NKG2D ligand expression 
in vivo, we will cross K-Ras G12D transgenic mice to NKG2D-deficient mice, 
and deplete immune cell subsets. More aggressive tumors with a faster 
kinetic would suggest a role for K-Ras G12D induces NKG2D ligand 
expression in immunosurveillance.  
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Supplementary Figure 1. Inhibition of IGFR, PDGFR and FGF/VEGFR do 
not impair NKG2D ligand expression levels. Fibroblasts were treated with 
the growth factor inhibitors (red lines) for IGFR (1 μM), PDGFR (2 μM), and 
FGF/VEGFR (2μM) or DMSO (blue lines) for 18 hours. Filled histograms and 
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